Pantoprazol Aurobindo (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Aurobindo, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Pantoprazol Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Pantoprazol Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Aurobindo is a proton pump inhibitor that addresses disorders linked to excess gastric acid secretion.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with gastrin‑producing tumors. - NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients requiring long‑term NSAID therapy.

Pantoprazol Aurobindo may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild, transient headache reported by some patients. - Diarrhea: loose stools occurring during early treatment. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach area. - Flatulence: increased gas formation. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea with abdominal cramping. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures. - Bone fracture risk: increased susceptibility to hip, wrist, or spine fractures with long‑term use. - Acute interstitial nephritis: kidney inflammation presenting as fever, rash, and reduced urine output. - Hepatotoxicity: elevated liver enzymes or jaundice.

Before initiating therapy with Pantoprazol Aurobindo, consider the following precautions:

- Assess renal function: dosage adjustment may be required in severe renal impairment. - Evaluate hepatic status: use with caution in patients with liver disease. - Review long‑term use: prolonged therapy may be linked to nutrient malabsorption and bone density loss. - Monitor for infections: increased risk of gastrointestinal infections such as C. difficile. - Pregnancy and lactation: weigh potential benefits against risks; consult a healthcare professional. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Aurobindo can affect the pharmacokinetics of several co‑administered medicines. Careful review of a patient’s medication list is recommended.

Major Interactions (Avoid): - Antifungal agents (ketoconazole, itraconazole): reduced absorption leading to therapeutic failure. - HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR; monitor coagulation parameters. - Methotrexate: possible accumulation and toxicity, especially at high doses. - Digoxin: modest rise in serum levels; observe for signs of digoxin toxicity.